[Parkinson disease: deep cerebral stimulation].
Identifieur interne : 003302 ( Main/Exploration ); précédent : 003301; suivant : 003303[Parkinson disease: deep cerebral stimulation].
Auteurs : P. Krack [France]Source :
- Revue neurologique [ 0035-3787 ] ; 2002.
English descriptors
- KwdEn :
- MESH :
- chemical : Levodopa.
- adverse effects : Electric Stimulation.
- diagnosis : Parkinson Disease.
- surgery : Parkinson Disease.
- therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Patient Selection, Subthalamic Nucleus.
Abstract
The effects of deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the internal pallidum (GPi) on the parkinsonian triad and on levodopa-induced dyskinesias are very similar. The antiakinetic effect of STN DBS seems to be slightly better. On the contrary to pallidal DBS, stimulation of the STN allows to reduce dopaminergic treatment by more than 50 p. 100 on average. Moreover, the current drain is smaller in STN. Thus, the STN is a low budget target compared to the GPi. STN DBS seems to be as effective on PD tremor as stimulation of the classic thalamic target, the ventral intermediate nucleus (Vim), whereas Vim stimulation has no effect on akinesia and very little on levodopa-induced dyskinesias. Thus, the STN has become the main target nucleus for DBS in PD, which is most often performed bilaterally in one surgical procedure. There is a good correlation of the preoperative response to levodopa and postoperative effects of bilateral STN DBS and this defines the patient population. Given the large patient population, simple guidelines for patient selection are developed. The referring physician can preselect patients based mainly on age (less than 70), absence of dementia and presence of severe disability related to motor fluctuations or dyskinesias. It is the responsibility of the operating centre to determine the levodopa response, to confirm the diagnosis, to rule out contraindications and to make sure that the medical treatment cannot be further optimised. Severe surgical complications with permanent sequels are relatively rare, about 1 p. 100 per implanted side. The patient selection, the precision of the surgery and the quality of the postoperative follow-up are the three main determinants of success.
PubMed: 12690673
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001153
- to stream PubMed, to step Curation: 001112
- to stream PubMed, to step Checkpoint: 001112
- to stream Ncbi, to step Merge: 000324
- to stream Ncbi, to step Curation: 000324
- to stream Ncbi, to step Checkpoint: 000324
- to stream Main, to step Merge: 003795
- to stream Main, to step Curation: 003302
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Parkinson disease: deep cerebral stimulation].</title><author><name sortKey="Krack, P" sort="Krack, P" uniqKey="Krack P" first="P" last="Krack">P. Krack</name><affiliation wicri:level="3"><nlm:affiliation>Département des Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire, INSERM U 318, Université Joseph-Fourier, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département des Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire, INSERM U 318, Université Joseph-Fourier, Grenoble</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12690673</idno><idno type="pmid">12690673</idno><idno type="wicri:Area/PubMed/Corpus">001153</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001153</idno><idno type="wicri:Area/PubMed/Curation">001112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001112</idno><idno type="wicri:Area/PubMed/Checkpoint">001112</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001112</idno><idno type="wicri:Area/Ncbi/Merge">000324</idno><idno type="wicri:Area/Ncbi/Curation">000324</idno><idno type="wicri:Area/Ncbi/Checkpoint">000324</idno><idno type="wicri:doubleKey">0035-3787:2002:Krack P:parkinson:disease:deep</idno><idno type="wicri:Area/Main/Merge">003795</idno><idno type="wicri:Area/Main/Curation">003302</idno><idno type="wicri:Area/Main/Exploration">003302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Parkinson disease: deep cerebral stimulation].</title><author><name sortKey="Krack, P" sort="Krack, P" uniqKey="Krack P" first="P" last="Krack">P. Krack</name><affiliation wicri:level="3"><nlm:affiliation>Département des Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire, INSERM U 318, Université Joseph-Fourier, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département des Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire, INSERM U 318, Université Joseph-Fourier, Grenoble</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Electric Stimulation (adverse effects)</term><term>Humans</term><term>Levodopa</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (surgery)</term><term>Parkinson Disease (therapy)</term><term>Patient Selection</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Electric Stimulation</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Middle Aged</term><term>Patient Selection</term><term>Subthalamic Nucleus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effects of deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the internal pallidum (GPi) on the parkinsonian triad and on levodopa-induced dyskinesias are very similar. The antiakinetic effect of STN DBS seems to be slightly better. On the contrary to pallidal DBS, stimulation of the STN allows to reduce dopaminergic treatment by more than 50 p. 100 on average. Moreover, the current drain is smaller in STN. Thus, the STN is a low budget target compared to the GPi. STN DBS seems to be as effective on PD tremor as stimulation of the classic thalamic target, the ventral intermediate nucleus (Vim), whereas Vim stimulation has no effect on akinesia and very little on levodopa-induced dyskinesias. Thus, the STN has become the main target nucleus for DBS in PD, which is most often performed bilaterally in one surgical procedure. There is a good correlation of the preoperative response to levodopa and postoperative effects of bilateral STN DBS and this defines the patient population. Given the large patient population, simple guidelines for patient selection are developed. The referring physician can preselect patients based mainly on age (less than 70), absence of dementia and presence of severe disability related to motor fluctuations or dyskinesias. It is the responsibility of the operating centre to determine the levodopa response, to confirm the diagnosis, to rule out contraindications and to make sure that the medical treatment cannot be further optimised. Severe surgical complications with permanent sequels are relatively rare, about 1 p. 100 per implanted side. The patient selection, the precision of the surgery and the quality of the postoperative follow-up are the three main determinants of success.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Grenoble</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Krack, P" sort="Krack, P" uniqKey="Krack P" first="P" last="Krack">P. Krack</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12690673
|texte= [Parkinson disease: deep cerebral stimulation].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12690673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |